As of Apr 20
| -0.05 / -0.21%|
The 9 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 25.00, with a high estimate of 37.00 and a low estimate of 17.00. The median estimate represents a +7.07% increase from the last price of 23.35.
The current consensus among 10 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.